Boundless Bio lures Berkley from Ionis to support clinical push
Boundless Bio lures Berkley from Ionis to support clinical push [...]
CANbridge, targeting gaps in AstraZeneca’s rare disease coverage, posts early-phase data on C5 inhibitor
CANbridge, targeting gaps in AstraZeneca’s rare disease coverage, posts early-phase [...]
Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck’s drug
Bayer ends work on cough med that passed phase 2b [...]
Sanofi ends two phase 1 cancer assets weeks after axing Sangamo deal
Sanofi ends two phase 1 cancer assets weeks after axing [...]
Sanofi ends 2 phase 1 cancer assets weeks after axing Sangamo deal
Sanofi ends 2 phase 1 cancer assets weeks after axing [...]
Resignation galore: Exicure CEO resigns, CTO departs, 3 board members exit after December woes
Resignation galore: Exicure CEO resigns, CTO departs, 3 board members [...]
UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx
UCB races to regulators after $2.5B rare disease bet delivers [...]
Remote possibilities: United BioSource teams with Seqster to boost decentralized study offering
Remote possibilities: United BioSource teams with Seqster to boost decentralized [...]
Pfizer’s $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies
Pfizer’s $130M Lyme disease vaccine advances to phase 3 after [...]
Unity once again lays off large number of staff, narrows focus to ophthalmology assets
Unity once again lays off large number of staff, narrows [...]